Clinical Trials List
2020-06-01 - 2027-11-06
Phase III
Recruiting8
ICD-9185
Malignant neoplasm of prostate
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/01
Investigators and Locations
Co-Principal Investigator
- Ching-Chia Li 未分科
- Hung-Lung Ke 未分科
- Hsiang Ying Lee 未分科
- Yung-Chin Lee 未分科
- Sheng-Chen Wen 未分科
- 黃俊農 未分科
- Shu-Pin Huang 未分科
- 李政學 未分科
- 阮雍順 未分科
- Tsung-Yi Huang 未分科
- Tsu-Ming Chien 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 沈書慧 未分科
- Yen-Hwa Chang 未分科
- Tzu-Hao Huang 未分科
- I-Shen Huang 未分科
- William Huang Division of Urology
- Yi-Hsiu Huang 未分科
- 潘競成 未分科
- 陳威任 未分科
- Tzu-Ping Lin 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Che-Hung Lin 未分科
- Yu-De Wang 未分科
- Po-Fan Hsieh 未分科
- Su-Peng Yeh 未分科
- Wei-Ching Lin 未分科
- Po-Jen Hsiao Division of Urology
- Hsi-Chin Wu 未分科
- Han Chang 未分科
- Ching-Chan Lin 未分科
- 謝德鈞 未分科
- Chao-Hsiang Chang 未分科
- Yi-Huei Chang Division of Urology
- Chi-Rei Yang 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yung-Chang Lin Division of Hematology & Oncology
- 陳東藝 Division of Cardiovascular Diseases
- Hong-Cheng Gan Division of Hematology & Oncology
- Rita cheng Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- I-hung Shao Division of Hematology & Oncology
- Chen Pang Hou Division of Hematology & Oncology
- 黃文冠
- Jing-Ren Tseng Division of Nuclear Medicine
- Kai-Jie Yu Division of Hematology & Oncology
- 張境夫 Division of Hematology & Oncology
- 張鈞弼 Division of Radiology
- PO-HUNG LIN Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳盈伸 Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
1000 participants